# Post-exposure Prophylaxis / Preemptive Therapy for SARS-Coronavirus-2

> **NCT04308668** · PHASE3 · COMPLETED · sponsor: **University of Minnesota** · enrollment: 1312 (actual)

## Conditions studied

- Corona Virus Infection
- Acute Respiratory Distress Syndrome
- SARS-CoV Infection
- Coronavirus
- Coronavirus Infections

## Interventions

- **DRUG:** Hydroxychloroquine
- **OTHER:** Placebo

## Key facts

- **NCT ID:** NCT04308668
- **Lead sponsor:** University of Minnesota
- **Sponsor class:** OTHER
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2020-03-17
- **Primary completion:** 2020-05-20
- **Final completion:** 2020-05-20
- **Target enrollment:** 1312 (ACTUAL)
- **Last updated:** 2021-05-13

## Collaborators

- [object Object]
- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04308668

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04308668, "Post-exposure Prophylaxis / Preemptive Therapy for SARS-Coronavirus-2". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT04308668. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*